GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sinocelltech Group Ltd (SHSE:688520) » Definitions » Forward PE Ratio

Sinocelltech Group (SHSE:688520) Forward PE Ratio : 0.00 (As of Jun. 10, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Sinocelltech Group Forward PE Ratio?

Sinocelltech Group's Forward PE Ratio for today is 0.00.

Sinocelltech Group's PE Ratio without NRI for today is 0.00.

Sinocelltech Group's PE Ratio for today is 0.00.


Sinocelltech Group Forward PE Ratio Historical Data

The historical data trend for Sinocelltech Group's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinocelltech Group Forward PE Ratio Chart

Sinocelltech Group Annual Data
Trend
Forward PE Ratio

Sinocelltech Group Quarterly Data
Forward PE Ratio

Competitive Comparison of Sinocelltech Group's Forward PE Ratio

For the Biotechnology subindustry, Sinocelltech Group's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sinocelltech Group's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sinocelltech Group's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Sinocelltech Group's Forward PE Ratio falls into.



Sinocelltech Group Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Sinocelltech Group  (SHSE:688520) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Sinocelltech Group Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Sinocelltech Group's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Sinocelltech Group (SHSE:688520) Business Description

Traded in Other Exchanges
N/A
Address
Kechuang Seventh Street, Beijing Economic and Technological Development Zone, Room 307, Building 5, Courtyard 31, Beijing, CHN, 100176
Sinocelltech Group Ltd is engaged in development and industrialization of biopharmaceutical products such as monoclonal antibodies, recombinant proteins and vaccines. The company has developed technology platforms in protein expression vectors, cell line development, serum-free medium development, stoichiometrically controlled fed-batch cell culture, process scale-up, and protein purification. Its capacities include stable CHO cell line development, cell banking and certification, serum-free and protein-free culture medium development, fed-batch cell culture process development, optimization, and process scale-up; protein purification development, and large scale production.
Executives
Xie Liang Zhi Director

Sinocelltech Group (SHSE:688520) Headlines

No Headlines